Orphazyme board member on expected EMA rejection: "The next few days will be hell"
Arimoclomol has shown statistical significance as a treatment for Niemann-Pick type C, says Orphazyme Deputy Chairman of the Board Bo Jesper Hansen, who does not understand how the EMA can reject the candidate or why they have tightened up the rules for statistical significance.
by christopher bundgaard, translated by catherine brett
As well as holding the deputy chair position on the board of Orphazyme, Bo Jesper Hansen is something of a celebrity within the treatment of rare diseases, having also co-founded Swedish Orphan Biovitrium, Sobi.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Orphazyme stock plummets following bad news from CHMP
For subscribers
Orphazyme predicts EU rejection after meeting with CHMP
For subscribers
